NO20030677D0 - Nye aporfinestere og deres anvendelse i terapi - Google Patents
Nye aporfinestere og deres anvendelse i terapiInfo
- Publication number
- NO20030677D0 NO20030677D0 NO20030677A NO20030677A NO20030677D0 NO 20030677 D0 NO20030677 D0 NO 20030677D0 NO 20030677 A NO20030677 A NO 20030677A NO 20030677 A NO20030677 A NO 20030677A NO 20030677 D0 NO20030677 D0 NO 20030677D0
- Authority
- NO
- Norway
- Prior art keywords
- aporphin
- therapy
- esters
- new
- new aporphin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002934A SE0002934D0 (sv) | 2000-08-17 | 2000-08-17 | New aporphine esters and in their use in therapy |
PCT/SE2001/001658 WO2002014279A1 (en) | 2000-08-17 | 2001-07-20 | New aporphine esters and their use in therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20030677D0 true NO20030677D0 (no) | 2003-02-11 |
NO20030677L NO20030677L (no) | 2003-03-05 |
NO324409B1 NO324409B1 (no) | 2007-10-08 |
Family
ID=20280719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20030677A NO324409B1 (no) | 2000-08-17 | 2003-02-11 | Nye aporfinderivater, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytiske preparater omfattende derivatene |
Country Status (19)
Country | Link |
---|---|
US (3) | US7238705B2 (no) |
EP (1) | EP1309553A1 (no) |
JP (1) | JP2004506041A (no) |
KR (1) | KR100865503B1 (no) |
CN (1) | CN1242991C (no) |
AU (2) | AU2001271228B2 (no) |
BR (1) | BR0113291A (no) |
CA (1) | CA2419842C (no) |
CZ (1) | CZ2003454A3 (no) |
EA (1) | EA006388B1 (no) |
HU (1) | HUP0301685A3 (no) |
IL (2) | IL154096A0 (no) |
MX (1) | MXPA03001465A (no) |
NO (1) | NO324409B1 (no) |
NZ (1) | NZ523893A (no) |
PL (1) | PL360089A1 (no) |
SE (1) | SE0002934D0 (no) |
WO (1) | WO2002014279A1 (no) |
ZA (1) | ZA200300828B (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0002934D0 (sv) * | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
SE0102036D0 (sv) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
BR0318360A (pt) * | 2003-06-19 | 2006-07-25 | Lotus Pharmaceutical Co Ltd | aporfina e oxoaporfina e o uso médico das mesmas |
US20070065463A1 (en) | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
AU2005232748A1 (en) | 2004-04-13 | 2005-10-27 | The Mclean Hospital Corporation | R(-)-11-hydroxyaporphine derivatives and uses thereof |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
US20110111014A1 (en) * | 2007-06-26 | 2011-05-12 | Parkinson's Institute | Methods and compositions for treatment of neurological disorders |
US8431591B2 (en) | 2007-07-12 | 2013-04-30 | The Mclean Hospital Corporation | R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof |
US20090124651A1 (en) | 2007-08-31 | 2009-05-14 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
TWI404702B (zh) * | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
ES2315203B1 (es) * | 2007-09-11 | 2010-01-13 | Universidade De Santiago De Compostela | Uso de oxoisoaporfinas y sus derivados como inhibidores selectivos de la monoamino oxidasa a. |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
JP2011526889A (ja) | 2008-06-30 | 2011-10-20 | アフギン ファーマ,エルエルシー | 局所局部的神経作用療法 |
EP2419508A4 (en) * | 2009-04-17 | 2012-11-14 | Somalabs Inc | METHOD OF INDUCING REWARD RESPONSE BY MODULATION OF DOPAMINERGIC SYSTEMS IN THE CENTRAL NERVOUS SYSTEM |
CN102480958B (zh) | 2009-06-12 | 2015-08-19 | Cynapsus疗法有限公司 | 舌下阿扑吗啡 |
KR101946774B1 (ko) | 2010-12-16 | 2019-02-11 | 선오비온 파마슈티컬스 인코포레이티드 | 설하 필름 |
HUE038787T2 (hu) * | 2011-02-11 | 2018-11-28 | Univ Michigan Regents | Tripeptid készítmények és alkalmazásuk diabétesz kezelésére |
CA3127926A1 (en) | 2015-04-21 | 2016-10-27 | Sunovion Pharmaceuticals Inc. | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
EP3314251A1 (en) | 2015-06-24 | 2018-05-02 | Koninklijke Philips N.V. | Sweat monitoring apparatus and monitoring method |
EP3740190A1 (en) | 2018-01-18 | 2020-11-25 | Leukos Biotech, S.L. | Apomorphine·palmitic acid cocrystal solid particle crystalline form |
US20210238124A1 (en) * | 2018-04-20 | 2021-08-05 | The General Hospital Corporation | Acetylated prodrugs for delivery across the blood-brain barrier |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4080456A (en) * | 1971-10-26 | 1978-03-21 | Schering Aktiengesellschaft | Diacylapomorphines |
AU3140577A (en) | 1976-12-13 | 1979-06-14 | Sterling Drug Inc | N-propylnorapormorphine diesters |
DE2717001C2 (de) | 1977-04-18 | 1984-06-20 | Karl O. Helm Ag, 2000 Hamburg | Arzneimittel mit antithrombotischer Wirkung |
EP0040074B1 (en) | 1980-05-08 | 1985-07-31 | Northeastern University | N-substituted aporphines, a method of inducing emesis and a method of controlling psychosis utilising the same |
US4353912A (en) * | 1980-05-08 | 1982-10-12 | Northeastern University | N-Haloalkyl nor apomorphines and method of inactivating dopamine receptor sites and enhancing dopaminergic activity therewith |
WO1990012574A1 (en) * | 1989-04-25 | 1990-11-01 | Northeastern University | Dopamine agonist compounds |
GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
GB9700878D0 (en) | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
IT1299566B1 (it) | 1998-07-17 | 2000-03-16 | Ifi Istituto Farmacoterapico I | Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina |
MXPA01011480A (es) | 1999-05-13 | 2002-06-04 | Unihart Corp | Composiciones farmaceuticas que comprenden apocodeina y/o sus derivados. |
CZ20023637A3 (cs) * | 2000-04-07 | 2003-02-12 | Tap Pharmaceutical Products, Inc. | Deriváty apomorfinu a způsoby jejich použití |
SE0102036D0 (sv) * | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
SE0002934D0 (sv) | 2000-08-17 | 2000-08-17 | Axon Biochemicals Bv | New aporphine esters and in their use in therapy |
EP1950203A1 (en) | 2007-01-24 | 2008-07-30 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds with ACAT, their preparation and use as medicaments |
-
2000
- 2000-08-17 SE SE0002934A patent/SE0002934D0/xx unknown
-
2001
- 2001-07-20 IL IL15409601A patent/IL154096A0/xx unknown
- 2001-07-20 CN CNB018142222A patent/CN1242991C/zh not_active Expired - Fee Related
- 2001-07-20 CZ CZ2003454A patent/CZ2003454A3/cs unknown
- 2001-07-20 WO PCT/SE2001/001658 patent/WO2002014279A1/en active IP Right Grant
- 2001-07-20 AU AU2001271228A patent/AU2001271228B2/en not_active Ceased
- 2001-07-20 NZ NZ523893A patent/NZ523893A/en not_active IP Right Cessation
- 2001-07-20 MX MXPA03001465A patent/MXPA03001465A/es active IP Right Grant
- 2001-07-20 AU AU7122801A patent/AU7122801A/xx active Pending
- 2001-07-20 EP EP01950203A patent/EP1309553A1/en not_active Withdrawn
- 2001-07-20 BR BR0113291-1A patent/BR0113291A/pt not_active Application Discontinuation
- 2001-07-20 EA EA200300266A patent/EA006388B1/ru not_active IP Right Cessation
- 2001-07-20 PL PL36008901A patent/PL360089A1/xx not_active Application Discontinuation
- 2001-07-20 CA CA2419842A patent/CA2419842C/en not_active Expired - Fee Related
- 2001-07-20 US US10/344,420 patent/US7238705B2/en not_active Expired - Lifetime
- 2001-07-20 KR KR1020037002274A patent/KR100865503B1/ko not_active IP Right Cessation
- 2001-07-20 JP JP2002519422A patent/JP2004506041A/ja active Pending
- 2001-07-20 HU HU0301685A patent/HUP0301685A3/hu unknown
-
2003
- 2003-01-23 IL IL154096A patent/IL154096A/en active IP Right Grant
- 2003-01-30 ZA ZA200300828A patent/ZA200300828B/en unknown
- 2003-02-11 NO NO20030677A patent/NO324409B1/no not_active IP Right Cessation
-
2005
- 2005-02-22 US US11/061,881 patent/US7332503B2/en not_active Expired - Lifetime
-
2008
- 2008-01-29 US US12/021,560 patent/US20080119504A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20030036703A (ko) | 2003-05-09 |
CN1242991C (zh) | 2006-02-22 |
IL154096A (en) | 2009-11-18 |
EP1309553A1 (en) | 2003-05-14 |
CZ2003454A3 (cs) | 2003-06-18 |
PL360089A1 (en) | 2004-09-06 |
NZ523893A (en) | 2003-10-31 |
BR0113291A (pt) | 2004-01-06 |
NO20030677L (no) | 2003-03-05 |
NO324409B1 (no) | 2007-10-08 |
IL154096A0 (en) | 2003-07-31 |
AU7122801A (en) | 2002-02-25 |
KR100865503B1 (ko) | 2008-10-28 |
US7238705B2 (en) | 2007-07-03 |
ZA200300828B (en) | 2004-05-17 |
HUP0301685A2 (hu) | 2003-08-28 |
MXPA03001465A (es) | 2004-12-13 |
EA200300266A1 (ru) | 2003-08-28 |
US7332503B2 (en) | 2008-02-19 |
US20040018956A1 (en) | 2004-01-29 |
US20050143408A1 (en) | 2005-06-30 |
EA006388B1 (ru) | 2005-12-29 |
SE0002934D0 (sv) | 2000-08-17 |
CA2419842A1 (en) | 2002-02-21 |
AU2001271228B2 (en) | 2006-02-02 |
CA2419842C (en) | 2011-10-18 |
WO2002014279A1 (en) | 2002-02-21 |
US20080119504A1 (en) | 2008-05-22 |
JP2004506041A (ja) | 2004-02-26 |
HUP0301685A3 (en) | 2010-03-29 |
CN1447792A (zh) | 2003-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20030677D0 (no) | Nye aporfinestere og deres anvendelse i terapi | |
DK1354888T3 (da) | Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter | |
NO20014560D0 (no) | Quinasoliner og terapautisk anvendelse derav | |
NO20023043L (no) | Substituerte oksazolidinoner og deres anvendelse innenfor feltet blodkoagulasjon | |
IS8329A (is) | Kínólínafleiður og notkun þeirra í meðferð | |
NO20022289D0 (no) | Ny anvendelse og nye N-azabisykloamidderivater | |
NO20014135L (no) | Nye sulfonamidforbindelser og deres anvendelse | |
NO20025227L (no) | Tropanderivater nyttige i terapi | |
NO20020343D0 (no) | Kaspase-inhibitorer og anvendelse derav | |
DK1578755T3 (da) | Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse | |
IS6656A (is) | Útskiptar kínasólínafleiður og notkun þeirra sem hemla | |
NO20032695D0 (no) | Karboksamidderivater og deres anvendelse ved behandling av tromboemboliskesykdommer | |
NO20025357D0 (no) | Antranylamider og deres anvendelse som legemidler | |
NO20015045D0 (no) | Diaminotiazoler og deres anvendelse til inhibering av proteinkinaser | |
DK1347955T3 (da) | Nye mandelsyrederivater og deres anvendelse som throbin-hæmmere | |
NO20053593D0 (no) | Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi | |
TWI349551B (en) | Thiophenepyrimidinone derivatives and their use in therapy | |
DK1392292T3 (da) | Pyranoindazoler og deres anvendelse til behandling af glaukom | |
DK1429769T3 (da) | Nye formuleringer og anvendelse deraf | |
NO20043370L (no) | N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer | |
NO20020031D0 (no) | Dihydrobenzodiazepiner og deres anvendelse ved behandling av dyslipidemi | |
NO20032340D0 (no) | Substituerte derivater av aminofuran-2-yl-eddiksyre og aminotien-2-yl-eddiksyre og deres anvendelse for behandling av migrene og smerte | |
ATA17962001A (de) | Wölb-verwind-komfort- und therapie-stütze | |
NO20030547L (no) | Azabicykliske derivater og deres terapeutiske anvendelse | |
NO20030822L (no) | Nye forbindelser og fremgangsmåter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |